Rejenevie Therapeutics is developing a heterochronic cell culture model in order to stimulate the function of hematopoietic stem cells (HSCs). The goal is to promote the rejuvenation of aging cells by providing them with youthful blood factors, a technique that is related to parabiosis, the connection of old and young vascular systems.

However, unlike in parabiosis, the company intends to extract these cells from the human body before rejuvenating them through the Transwell system, in which cells interact but do not mix. It started a Phase 2 clinical trial of its lead product, AR-100, an autologous mobilized peripheral blood cell therapy, at Okyanos in the Bahamas, but this had to be suspended due to Hurricane Dorian. There has been no news as to when it will resume.

Rejenevie firmly sees its approach as part of the Hallmarks of Aging and lists the Hallmarks on its website.